Skip to main content

ScholarsBetaWeill Cornell Medicine

Browse About Sign in

Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research2

FiltersClear all

Status

Completed2

Study type

Expanded access2

Phase

Not reported2
Phase 18
Phase 1/26
Phase 25
Phase 32
Not applicable2
Phase 2/31
Phase 41

Investigator

Ruben Niesvizky2

Department

Medicine2

Condition

Recurrence2
COVID-196
Multiple Myeloma5
Atrial Fibrillation4
Liver Cirrhosis4

Show all 50

Intervention type

Drug2

Sponsor type

Industry2

Start date

to

Not reported×Recurrence×Clear all

Showing 1–2 of 2 studiesSort:

CompletedExpanded accessNCT05462639 ↗
ELRANATAMAB (PF-06863135) MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY

Show fewer

Ruben NiesvizkyPI

Intervention: Drug: Elranatamab (PF-06863135)
Dates: Started Dec 2022
Sponsor: Pfizer, Inc.

Multiple Myeloma

CompletedExpanded accessNCT05757973 ↗

64407564MMY4003: 64407564MMY4003 - Talquetamab NPP Global

Ruben NiesvizkyPI

Intervention: Drug: Talquetamab
Dates: Started Jul 2023
Sponsor: Janssen Research & Development, LLC

Relapsed or Refractory Multiple Myeloma